Cargando…

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

OBJECTIVE: To estimate US public investment in the development of mRNA covid-19 vaccines. DESIGN: Retrospective cohort study. SETTING: Publicly funded science from January 1985 to March 2022. DATA SOURCES: National Institutes of Health (NIH) Report Portfolio Online Reporting Tool Expenditures and Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalani, Hussain S, Nagar, Sarosh, Sarpatwari, Ameet, Barenie, Rachel E, Avorn, Jerry, Rome, Benjamin N, Kesselheim, Aaron S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975718/ https://www.ncbi.nlm.nih.gov/pubmed/36858453 http://dx.doi.org/10.1136/bmj-2022-073747

Ejemplares similares

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Public funding for transformative drugs: the case of sofosbuvir
por: Barenie, Rachel E., et al.
Publicado: (2021)

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
por: Rome, Benjamin N., et al.
Publicado: (2021)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
por: Brown, Beatrice L., et al.
Publicado: (2023)

Public sector financial support for late stage discovery of new drugs in the United States: cohort study
por: Nayak, Rahul K, et al.
Publicado: (2019)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Competition and price among brand-name drugs in the same class: A systematic review of the evidence
por: Sarpatwari, Ameet, et al.
Publicado: (2019)

Clinicians’ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation
por: Kesselheim, Aaron S., et al.
Publicado: (2014)

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
Publicado: (2023)

Outcomes of the 340B Drug Pricing Program: A Scoping Review
por: Knox, Ryan P., et al.
Publicado: (2023)

Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review
por: Austad, Kirsten E., et al.
Publicado: (2011)

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
por: Roberts, Thomas J., et al.
Publicado: (2023)

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine
por: Wang, Bo, et al.
Publicado: (2017)

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study
por: Liu, Michael, et al.
Publicado: (2020)

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
por: Van de Wiele, Victor L, et al.
Publicado: (2022)

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
por: Sarpatwari, Ameet, et al.
Publicado: (2023)

Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
por: Bothwell, Laura E, et al.
Publicado: (2018)

Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
por: Gyawali, Bishal, et al.
Publicado: (2021)

Mifepristone, preemption, and public health federalism
por: Zettler, Patricia J, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use
por: Sarpatwari, Ameet, et al.
Publicado: (2022)

Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims
por: Desai, Rishi J., et al.
Publicado: (2019)

The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid
por: Messinger, John C, et al.
Publicado: (2022)

The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
por: Bendicksen, Liam, et al.
Publicado: (2022)

COVID-19 antivirals must not affect HIV drug supply
por: Barber, Melissa, et al.
Publicado: (2022)

Association of Medical Students' Reports of Interactions with the Pharmaceutical and Medical Device Industries and Medical School Policies and Characteristics: A Cross-Sectional Study
por: Yeh, James S., et al.
Publicado: (2014)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023)

Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization
por: Rome, Benjamin N., et al.
Publicado: (2021)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study
por: Mostaghim, Sana R, et al.
Publicado: (2017)

Navigating U.S. investment markets
por: Lydon, Tom
Publicado: (2010)

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k8slrmrdbjts53s5u4gd8e7m6d